An amince da Pembrolizumab a China don maganin HCC mara tsaftacewa tare da Lenvatinib da TACE

Kwanan nan, Merck & Co., Inc. (Merck) ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta kasar Sin ta amince da maganin hana PD-1, pembrolizumab, don amfani da shi tare da lenvatinib da kuma transarterial chemoembolization (TACE) don maganin marasa lafiya da ba za a iya cirewa ba, wanda ba ya yada cutar kansar hanta.

Amincewar wannan sabon alamar ta dogara ne akan bayanai daga gwajin asibiti na Phase III LEAP-012. A cikin wannan binciken Phase III (LEAP-012), an yi wa marasa lafiya 480 rajista kuma an ba su izinin karɓar lenvatinib da TACE da pembrolizumab (n=237) ko TACE da dual placebo (n=243).

Sakamakon ya nuna cewa matsakaicin rayuwa ba tare da ci gaba ba (PFS) ya kasance watanni 14.6 a cikin lenvatinib da ƙungiyar TACE da pembrolizumab, idan aka kwatanta da watanni 10.0 a cikin ƙungiyar placebo. Jimlar rayuwa (OS) na watanni 24 shine 75% da 69%, bi da bi.

Lenvatinibwani maganin hana kinase ne da ake amfani da shi wajen magance wasu nau'ikan ciwon daji. Masu hana kinase su ne masu hana enzyme waɗanda ke toshe aikin kinases na furotin ɗaya ko fiye.

Pembrolizumab wani maganin rigakafi ne na IgG4 kappa wanda aka tsara shi don yaƙar saman ƙwayar halittar ɗan adam PD-1 (wanda aka tsara don karɓar mutuwa-1) akan lymphocytes. Mai karɓar PD-1 yana ba da muhimmin "dubawa na rigakafi," wanda ke taimakawa hana tsarin garkuwar jiki kai hari kan kansa. Wasu nau'ikan ciwace-ciwacen suna da babban bayyanar PD-L1 (wanda aka tsara don karɓar mutuwa ligand-1). Sauran nau'ikan ciwace-ciwacen suna amfani da juriyar rigakafi mai daidaitawa inda suke ɗaukar ilimin halittar halitta na PD-L1 (kariya daga lalacewa ta hanyar rigakafi daga cututtuka) kuma suna daidaita shi zuwa ga martanin hana ƙari. Lokacin da PD-L1 ta shiga PD-1, aikin ƙwayoyin T ya zama abin hanawa; pembrolizumab yana toshe samuwar hadaddun PD-1: PDL-1 wanda ke ba da damar inganta kisan da aka yi wa ƙwayoyin T.

A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.

Lambar Waya: 4008803716

Email：myimmnet@163.com